Insilico Medicine Nominates ISM5059, the Peripheral-restricted NLRP3 Inhibitor as Preclinical Candidate, for the Treatment of Multiple Inflammatory and Metabolism Indications
NLRP3 is a validated anti-inflammatory target that mediates the release of proinflammatory cytokines IL-1β and IL-18, and ISM5059 targets systemic inflammatory conditions by targeting NLRP3 and blocking the inflammatory cascade at its source. Unlike...
FERRETTI INTERNATIONAL HOLDING S.P.A. EXPRESSES NO INTENTION TO SUPPORT THE PARTIAL PUBLIC TENDER OFFER LAUNCHED BY KKCG MARITIME
REAFFIRMS ITS LONG-TERM INVESTMENT IN THE COMPANY AND CONFIRMS ITS INTENTION TO NOMINATE THE MAJORITY OF THE DIRECTORS OF FERRETTI S.P.A. MILAN, Jan. 22, 2026 /PRNewswire/ -- Ferretti International Holding S.p.A. ("FIH"), as the controlling...